The Relationships Between Perioperative CEA, CA 19-9, and CA 72-4 and Recurrence in Gastric Cancer Patients After Curative Radical Gastrectomy

被引:81
|
作者
Kim, Dae Hoon [1 ]
Oh, Seung Jong [1 ]
Oh, Cheong Ah [1 ]
Choi, Min Gew [1 ]
Noh, Jae Hyung [1 ]
Sohn, Tae Sung [1 ]
Bae, Jae Moon [1 ]
Kim, Sung [1 ]
机构
[1] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Surg, Seoul 135710, South Korea
关键词
gastric cancer; CEA; CA; 19-9; 72-4; PREOPERATIVE SERUM-LEVELS; CARCINOEMBRYONIC ANTIGEN; PROGNOSTIC VALUE; FOLLOW-UP; TUMOR-MARKERS; CA-72-4; CARCINOMA; RESECTION; SURVIVAL; SURGERY;
D O I
10.1002/jso.21919
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and Objectives: The correlation between perioperative CEA, CA 19-9, and CA 72-4 and recurrence of gastric cancer has not been clarified. The aim of this study was to investigate the relationships between perioperative CEA, CA 19-9, and CA 72-4 and recurrence of gastric cancer. Methods: We retrospectively analyzed the relationships between the tumor markers CEA, CA 19-9, and CA 72-4 and recurrence of gastric cancer. Results: In patients with early gastric cancer, the recurrence sensitivity of postoperative CEA, CA 19-9, and CA 72-4 was 40.0, 5.6, and 2.8%, respectively. And in patients with advanced gastric cancer, the recurrence sensitivity of postoperative CEA, CA 19-9, and CA 72-4 was 100.0, 68.2, and 51.3%, respectively. Multivariate analyses showed that an increase in postoperative CEA in early gastric cancer was an independent prognostic factor of recurrence. In patients with advanced gastric cancer, age >60 years, stage III, and postoperative CEA increase and CA 72-4 increase were independent prognostic factors of recurrence. Conclusions: For patients with advanced gastric cancer, CEA, CA 19-9, and CA 72-4 are considered useful for follow-up tests. Although, CEA is considered useful for follow-up test for patients with early gastric cancer, but CA19-9 and CA72-4 are less useful due to their low sensitivity. J. Surg. Oncol. 2011;104:585-591. (C) 2011 Wiley Periodicals, Inc.
引用
收藏
页码:585 / 591
页数:7
相关论文
共 50 条
  • [31] Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence
    Lai, IR
    Lee, WJ
    Huang, MT
    Lin, HH
    HEPATO-GASTROENTEROLOGY, 2002, 49 (46) : 1157 - 1160
  • [32] Measurement of serum CA 19-9 may be more valuable than CEA in prediction of recurrence in patients with gastric cancer
    Tas, F
    Aykan, F
    Aydiner, A
    Yasasever, V
    Topuz, E
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2001, 24 (02): : 148 - 149
  • [33] Differences and correlation of serum CEA, CA19-9 and CA72-4 in gastric cancer
    Yu, Junxiu
    Zhang, Shuguang
    Zhao, Bingbo
    MOLECULAR AND CLINICAL ONCOLOGY, 2016, 4 (03) : 441 - 449
  • [34] Tumour markers in uraemia: Carbohydrate antigen CA 72-4, carcinoembryonic antigen and carbohydrate antigen CA 19-9
    FernandezFernandez, L
    Asensio, M
    Tejero, E
    Rabadan, L
    Lopez, L
    ANNALS OF CLINICAL BIOCHEMISTRY, 1996, 33 : 563 - 564
  • [35] CEA and CA 19-9 are Still Valuable Markers for the Prognosis of Colorectal and Gastric Cancer Patients
    Sisik, Abdullah
    Kaya, Mustafa
    Bas, Gurhan
    Basak, Fatih
    Alimoglu, Orhan
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2013, 14 (07) : 4289 - 4294
  • [36] Clinical significance and diagnostic value of serum CEA, CA19-9 and CA72-4 in patients with gastric cancer
    Liang, Yao
    Wang, Wei
    Fang, Cheng
    Raj, Seeruttun Sharvesh
    Hu, Wan-Ming
    Li, Qi-Wen
    Zhou, Zhi-Wei
    ONCOTARGET, 2016, 7 (31) : 49565 - 49573
  • [37] Clinical significance and prognostic value of CA72-4 compared with CEA and CA19-9 in patients with gastric cancer
    Ychou, M
    Duffour, J
    Kramar, A
    Gourgou, S
    Grenier, J
    DISEASE MARKERS, 2000, 16 (3-4) : 105 - 110
  • [38] THE USE OF CEA AND CA 19-9 IN THE FOLLOW-UP AFTER CURATIVE RESECTION OF COLORECTAL-CANCER
    STAPEL, A
    FRANKE, U
    PUTZKI, H
    ZENTRALBLATT FUR CHIRURGIE, 1992, 117 (02): : 77 - 80
  • [39] CLINICAL EVALUATION OF CEA, CA125, CA19-9 AND CA72-4 IN GASTRIC CANCER PATIENTS WITH ADJUVANT CHEMOTHERAPY
    Abbas, M.
    Fransis, S.
    Naveed, M.
    Mohammad, I. S.
    Tengli, C.
    Nepal, A.
    Thao, D. T.
    Meiqi, S.
    Dingding, C.
    VALUE IN HEALTH, 2017, 20 (09) : A732 - A732
  • [40] Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy
    Zhipeng Sun
    Nengwei Zhang
    World Journal of Surgical Oncology, 12